Nuveen S&P 500 Buy-Write Income Fund Balance Sheet Health
Financial Health criteria checks 4/6
Nuveen S&P 500 Buy-Write Income Fund has a total shareholder equity of $1.5B and total debt of $27.0M, which brings its debt-to-equity ratio to 1.9%. Its total assets and total liabilities are $1.5B and $58.1M respectively. Nuveen S&P 500 Buy-Write Income Fund's EBIT is $12.0M making its interest coverage ratio 131.6. It has cash and short-term investments of $553.0.
Key information
1.9%
Debt to equity ratio
US$27.00m
Debt
| Interest coverage ratio | 131.6x |
| Cash | US$553.00 |
| Equity | US$1.45b |
| Total liabilities | US$58.14m |
| Total assets | US$1.51b |
Recent financial health updates
No updates
Recent updates
BXMX: Covered Call Fund - A Superior Choice To XYLD
May 02BXMX: Reliable Income But Don't Expect Any Growth
Jan 29Why We Prefer BXMX's 7.7% Yield Over XYLD's 11.3%
Nov 14BXMX: Discount Opens Up
Aug 22BXMX: Buy-Write CEF Outperforming JEPI, 7% Yield
May 23Nuveen S&P 500 Buy-Write Income Fund declares $0.2365 dividend
Dec 06Nuveen S&P 500 Buy-Write Income Fund goes ex-dividend tomorrow
Sep 13Nuveen S&P 500 Buy-Write Income Fund, 7.2% Yield
Jul 28BXMX: A 5.9% Yielding Vehicle For Rangebound Markets
Sep 29BXMX: A Supplement To Your DGI Portfolio
Aug 02BXMX: An Overwrite Strategy Focused On The S&P 500
May 07BXMX: A Good Alternative To Euphoric Indices
Dec 16Nuveen S&P 500 Buy-Write Income Fund declares $0.215 dividend
Dec 02Financial Position Analysis
Short Term Liabilities: BXMX's short term assets ($63.9M) exceed its short term liabilities ($58.1M).
Long Term Liabilities: BXMX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BXMX's net debt to equity ratio (1.9%) is considered satisfactory.
Reducing Debt: BXMX's debt to equity ratio has increased from 0% to 1.9% over the past 5 years.
Debt Coverage: Insufficient data to determine if BXMX's debt is well covered by operating cash flow.
Interest Coverage: BXMX's interest payments on its debt are well covered by EBIT (131.6x coverage).